Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis

Min Jiang, Yufei Yan, Kai Yang, Zhuochao Liu, Jin Qi, Hanbing Zhou, Niandong Qian, Qi Zhou, Tianqi Wang, Xing Xu, Xiangshu Xiao, Lianfu Deng

Research output: Contribution to journalArticle

Abstract

Bone is the most common metastatic site for breast cancer. The excessive osteoclast activity in the metastatic bone lesions often produces osteolysis. The cyclic-AMP (cAMP)-response element binding protein (CREB) serves a variety of biological functions including the transformation and immortalization of breast cancer cells. In addition, evidence has shown that CREB plays a key role in osteoclastgenesis and bone resorption. Small organic molecules with good pharmacokinetic properties and specificity, targeting CREB-CBP (CREB-binding protein) interaction to inhibit CREB-mediated gene transcription have attracted more considerations as cancer therapeutics. We recently identified naphthol AS-E (nAS-E) as a cell-permeable inhibitor of CREB-mediated gene transcription through inhibiting CREB-CBP interaction. In this study, we tested the effect of nAS-E on breast cancer cell proliferation, survival, migration as well as osteoclast formation and bone resorption in vitro for the first time. Our results demonstrated that nAS-E inhibited breast cancer cell proliferation, migration, survival and suppressed osteoclast differentiation as well as bone resorption through inhibiting CREB-CBP interaction. In addition, the in vivo effect of nAS-E in protecting against breast cancer-induced osteolysis was evaluated. Our results indicated that nAS-E could reverse bone loss induced by MDA-MB-231 tumour. These results suggest that small molecules targeting CREB-CBP interaction to inhibit CREB-mediated gene transcription might be a potential approach for the treatment of breast cancer bone metastasis.

Original languageEnglish (US)
JournalJournal of Cellular and Molecular Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cyclic AMP Response Element-Binding Protein
Bone Neoplasms
Protein Binding
Carrier Proteins
Breast Neoplasms
Neoplasm Metastasis
Osteoclasts
Bone Resorption
Osteolysis
Bone and Bones
Cell Proliferation
naphthol AS-E
Genes
Cell Movement
Neoplasms
Cell Survival
Pharmacokinetics

Keywords

  • breast cancer bone metastasis
  • CBP
  • CREB
  • naphthol AS-E
  • osteoclasts

ASJC Scopus subject areas

  • Molecular Medicine
  • Cell Biology

Cite this

Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis. / Jiang, Min; Yan, Yufei; Yang, Kai; Liu, Zhuochao; Qi, Jin; Zhou, Hanbing; Qian, Niandong; Zhou, Qi; Wang, Tianqi; Xu, Xing; Xiao, Xiangshu; Deng, Lianfu.

In: Journal of Cellular and Molecular Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Jiang, Min ; Yan, Yufei ; Yang, Kai ; Liu, Zhuochao ; Qi, Jin ; Zhou, Hanbing ; Qian, Niandong ; Zhou, Qi ; Wang, Tianqi ; Xu, Xing ; Xiao, Xiangshu ; Deng, Lianfu. / Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis. In: Journal of Cellular and Molecular Medicine. 2018.
@article{103781f946b740ffaf9832d5d558cd30,
title = "Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis",
abstract = "Bone is the most common metastatic site for breast cancer. The excessive osteoclast activity in the metastatic bone lesions often produces osteolysis. The cyclic-AMP (cAMP)-response element binding protein (CREB) serves a variety of biological functions including the transformation and immortalization of breast cancer cells. In addition, evidence has shown that CREB plays a key role in osteoclastgenesis and bone resorption. Small organic molecules with good pharmacokinetic properties and specificity, targeting CREB-CBP (CREB-binding protein) interaction to inhibit CREB-mediated gene transcription have attracted more considerations as cancer therapeutics. We recently identified naphthol AS-E (nAS-E) as a cell-permeable inhibitor of CREB-mediated gene transcription through inhibiting CREB-CBP interaction. In this study, we tested the effect of nAS-E on breast cancer cell proliferation, survival, migration as well as osteoclast formation and bone resorption in vitro for the first time. Our results demonstrated that nAS-E inhibited breast cancer cell proliferation, migration, survival and suppressed osteoclast differentiation as well as bone resorption through inhibiting CREB-CBP interaction. In addition, the in vivo effect of nAS-E in protecting against breast cancer-induced osteolysis was evaluated. Our results indicated that nAS-E could reverse bone loss induced by MDA-MB-231 tumour. These results suggest that small molecules targeting CREB-CBP interaction to inhibit CREB-mediated gene transcription might be a potential approach for the treatment of breast cancer bone metastasis.",
keywords = "breast cancer bone metastasis, CBP, CREB, naphthol AS-E, osteoclasts",
author = "Min Jiang and Yufei Yan and Kai Yang and Zhuochao Liu and Jin Qi and Hanbing Zhou and Niandong Qian and Qi Zhou and Tianqi Wang and Xing Xu and Xiangshu Xiao and Lianfu Deng",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/jcmm.14024",
language = "English (US)",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis

AU - Jiang, Min

AU - Yan, Yufei

AU - Yang, Kai

AU - Liu, Zhuochao

AU - Qi, Jin

AU - Zhou, Hanbing

AU - Qian, Niandong

AU - Zhou, Qi

AU - Wang, Tianqi

AU - Xu, Xing

AU - Xiao, Xiangshu

AU - Deng, Lianfu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Bone is the most common metastatic site for breast cancer. The excessive osteoclast activity in the metastatic bone lesions often produces osteolysis. The cyclic-AMP (cAMP)-response element binding protein (CREB) serves a variety of biological functions including the transformation and immortalization of breast cancer cells. In addition, evidence has shown that CREB plays a key role in osteoclastgenesis and bone resorption. Small organic molecules with good pharmacokinetic properties and specificity, targeting CREB-CBP (CREB-binding protein) interaction to inhibit CREB-mediated gene transcription have attracted more considerations as cancer therapeutics. We recently identified naphthol AS-E (nAS-E) as a cell-permeable inhibitor of CREB-mediated gene transcription through inhibiting CREB-CBP interaction. In this study, we tested the effect of nAS-E on breast cancer cell proliferation, survival, migration as well as osteoclast formation and bone resorption in vitro for the first time. Our results demonstrated that nAS-E inhibited breast cancer cell proliferation, migration, survival and suppressed osteoclast differentiation as well as bone resorption through inhibiting CREB-CBP interaction. In addition, the in vivo effect of nAS-E in protecting against breast cancer-induced osteolysis was evaluated. Our results indicated that nAS-E could reverse bone loss induced by MDA-MB-231 tumour. These results suggest that small molecules targeting CREB-CBP interaction to inhibit CREB-mediated gene transcription might be a potential approach for the treatment of breast cancer bone metastasis.

AB - Bone is the most common metastatic site for breast cancer. The excessive osteoclast activity in the metastatic bone lesions often produces osteolysis. The cyclic-AMP (cAMP)-response element binding protein (CREB) serves a variety of biological functions including the transformation and immortalization of breast cancer cells. In addition, evidence has shown that CREB plays a key role in osteoclastgenesis and bone resorption. Small organic molecules with good pharmacokinetic properties and specificity, targeting CREB-CBP (CREB-binding protein) interaction to inhibit CREB-mediated gene transcription have attracted more considerations as cancer therapeutics. We recently identified naphthol AS-E (nAS-E) as a cell-permeable inhibitor of CREB-mediated gene transcription through inhibiting CREB-CBP interaction. In this study, we tested the effect of nAS-E on breast cancer cell proliferation, survival, migration as well as osteoclast formation and bone resorption in vitro for the first time. Our results demonstrated that nAS-E inhibited breast cancer cell proliferation, migration, survival and suppressed osteoclast differentiation as well as bone resorption through inhibiting CREB-CBP interaction. In addition, the in vivo effect of nAS-E in protecting against breast cancer-induced osteolysis was evaluated. Our results indicated that nAS-E could reverse bone loss induced by MDA-MB-231 tumour. These results suggest that small molecules targeting CREB-CBP interaction to inhibit CREB-mediated gene transcription might be a potential approach for the treatment of breast cancer bone metastasis.

KW - breast cancer bone metastasis

KW - CBP

KW - CREB

KW - naphthol AS-E

KW - osteoclasts

UR - http://www.scopus.com/inward/record.url?scp=85056765325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056765325&partnerID=8YFLogxK

U2 - 10.1111/jcmm.14024

DO - 10.1111/jcmm.14024

M3 - Article

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

ER -